Insulin secretagogues such as sulfonylureas and glinides have been widely used to treat patients with type 2 diabetes, but can increase the risk of hypoglycemia since they trigger insulin release from pancreatic islets independent of ambient glucose levels [4]. Here, INS is linked to Hypoglycemia.